Amount receivable upon achievement of milestone by entity under research and development agreement.

No definition available.

Name:	opht_ResearchAndDevelopmentArrangementAggregateAmountReceivableUponAchievementOfMilestone
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the amount of patient enrollment-based milestone revenue achieved by the entity.

+ References

No definition available.

+ Details

Name:	opht_ResearchAndDevelopmentArrangementAmountOfEnrollmentBasedMilestoneAchieved
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of milestone payments received under the agreement.

+ References

No definition available.

+ Details

Name:	opht_ResearchAndDevelopmentArrangementMilestonePaymentsReceived
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the amount of upfront fees received under the agreement.

+ References

No definition available.

+ Details

Name:	opht_ResearchAndDevelopmentArrangementUpfrontFeesReceived
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=opht_NovartisPharmaAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=opht_LicensingAndCommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opht_MilestoneEventsAxis=opht_AchievementOfSpecifiedPatientEnrollmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=opht_LicensingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=opht_ResearchAndDevelopmentActivitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opht_MilestoneEventsAxis=opht_AchievementOfSpecifiedMarketingApprovalMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	opht_MilestoneEventsAxis=opht_AchievementOfSpecifiedCommercialSaleMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Licensing and Commercialization Agreement with Novartis Pharma AG (Details) - Novartis Pharma AG - USD ($) $ in Millions		1 Months Ended					3 Months Ended	6 Months Ended	7 Months Ended
	May. 19, 2014	Apr. 30, 2015	Mar. 31, 2015	Oct. 31, 2014	Sep. 30, 2014	May. 31, 2014	Jun. 30, 2015	Jun. 30, 2015	Mar. 31, 2015
Agreement
Upfront fees received						$ 200.0
Patient enrollment-based milestone revenue achieved			$ 50.0		$ 50.0				$ 100.0
Licensing and Commercialization Agreement
Agreement
Upfront fees received	$ 200.0
Licensing and Commercialization Agreement \| Achievement of specified patient enrollment milestones
Agreement
Milestone payment received		$ 50.0		$ 50.0
Patient enrollment-based milestone revenue achieved			$ 50.0		$ 50.0				$ 100.0
Recognized revenues							$ 1.6	$ 43.3
Licensing and Commercialization Agreement \| Achievement of specified patient enrollment milestones \| Maximum
Agreement
Aggregate amount receivable on achievement of milestone							130.0	130.0
Licensing and Commercialization Agreement \| Achievement of specified patient enrollment milestones \| License revenue
Agreement
Recognized revenues								38.1
Licensing and Commercialization Agreement \| Achievement of specified patient enrollment milestones \| Research and development activity revenue
Agreement
Recognized revenues							1.6	5.2
Licensing and Commercialization Agreement \| Achievement of specified regulatory approval milestones \| Maximum
Agreement
Aggregate amount receivable on achievement of milestone							300.0	300.0
Licensing and Commercialization Agreement \| Achievement of specified commercial sale milestone \| Maximum
Agreement
Aggregate amount receivable on achievement of milestone							$ 400.0	$ 400.0